The primary aim of the present study was to evaluate the impact of 8 weeks of VLCKD on NAFLD, which was analysed with transient elastography (FibroScan) and FLI, and on changes in metabolic biomarkers (insulin, TSH, FT3, FT4, glucose, insulin resistance, triglycerides, total, HDL and LDL-cholesterol, uric acid, and vitamin D), and anthropometric (BMI and waist circumference [WC]) and body composition parameters (fat mass and fat-free mass measured by bioimpedance) in a group of obese/overweight patients without apparent comorbidities. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.